Perspective Therapeutics (CATX) Profit After Tax (2010 - 2026)

Perspective Therapeutics (CATX) has 17 years of Profit After Tax data on file, last reported at -$26.2 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax fell 44.08% year-over-year to -$26.2 million; the trailing twelve-month figure through Mar 2026 stood at -$111.0 million (down 30.35% YoY), and the FY2025 full-year result was -$103.1 million, down 30.07% from the prior year.
• Profit After Tax advanced to -$26.2 million in Q1 2026, from -$37.5 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$371000.0 in Q1 2023 to a low of -$40.2 million in Q4 2024.
• A 5-year average of -$16.2 million and a median of -$12.3 million in 2024 frame the typical range for Profit After Tax.
• Across the five-year window, Profit After Tax jumped 72.46% in 2023 and slumped 3211.05% in 2024, its largest moves.
• Tracing CATX's Profit After Tax over 5 years: stood at -$7.3 million in 2022, then slumped by 236.4% to -$24.7 million in 2023, then sank by 62.79% to -$40.2 million in 2024, then gained by 6.67% to -$37.5 million in 2025, then soared by 30.14% to -$26.2 million in 2026.
• Business Quant data shows CATX's Profit After Tax at -$26.2 million in Q1 2026, -$37.5 million in Q4 2025, and -$25.9 million in Q3 2025.